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If you can talk brilliantly about a problem, 
it can create the consoling illusion that it has been mastered. 
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ABSTRACT 
Trauma, “the neglected disease of modern society”, is a global health concern of enormous 
proportions. Knowledge about factors associated with trauma occurrence, complications and 
outcome is highly valuable for the improvement of trauma care. This thesis, aiming at deeper 
knowledge regarding trauma occurrence and outcome, used regional and national registers in 
four epidemiological studies with different methodologies. 
Prior to injury, trauma patients were treated for psychiatric disorders, substance abuse and 
somatic disorders to a greater extent than matched controls. Moreover, low income and low 
education, psychiatric disorders, substance abuse and somatic disorders were all independent 
risk factors for trauma after adjustment for confounders. These insights could facilitate 
implementation of injury prevention strategies. 
Severely injured patients that use β-adrenergic receptor antagonists (β-blockers) at the time of 
trauma had an increased mortality compared to non-users, β-blockers could thus be seen as an 
indicator for increased risk of death. However, after adjustment for relevant confounders no 
increased risk, or benefit, of β-blockers per se was noted. The protective effect of β-blockade 
after severe trauma suggested by previous reports could not be supported. Prospective 
randomized trials are needed to elucidate a role, if any, for β-blockade in the trauma setting. 
Acute kidney injury (AKI) affected one quarter of patients treated in the intensive care unit 
(ICU) following severe trauma. AKI was strongly associated with increased risk of death at 
30 days and after one year. For those treated with renal replacement therapy the risk of 
chronic dialysis dependency after the intensive care period appears to be very low. 
Comorbidities such as diabetes mellitus as well as greater injury severity were strongly 
associated with post-injury AKI. Among preventable factors an association between 
resuscitation with hydroxyethyl starch (HES) and increased risk of AKI warrants caution. 
Administration of nephrotoxic substances should be avoided and targeted interventions may 
be provided to the patient at risk. 
Finally, trauma patients had a sustained increase in mortality several years after the index 
trauma. External causes, including new trauma, were far more common causes of late death 
in injured patients than in the background population. These findings support the concept of 
trauma recidivism. Two subgroups of deceased individuals could be identified; younger 
patients with a high prevalence of psychiatric disorders and substance abuse dying from 
external causes including suicide, and an older subgroup with a burden of somatic 
comorbidities dying from cardiovascular disorders and neoplasms. These findings emphasize 
the need for improved follow-up strategies and secondary prevention. 
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1 INTRODUCTION 
A severe traumatic injury is a devastating event for an individual and a challenge for health 
care systems and societies. It is undeniably a major global health concern that causes the 
death of millions every year, leaving many more injured. Moreover, in contrast to many other 
diseases, it predominantly affects younger individuals. 
The development of dedicated trauma centers in many parts of the world has contributed to 
the decrease in trauma-related mortality noted in the last decades, but many challenges 
remain. It is of utmost importance that academic trauma centers are involved in all aspects of 
trauma care and research; organization, injury prevention, the pre-hospital phase, initial 
resuscitation and surgery, ICU treatment, in-hospital care, rehabilitation and long-term follow 
up. In this context, the majority of trauma studies have focused on initial resuscitation and 
surgery. 
This thesis, based on four included studies, addresses several aspects of trauma with a focus 
on risk factors and short- and long-term mortality. The aim was to elucidate factors that 
contribute to the trauma patient’s transition from health to illness, and eventually death. In 
study I, individual risk factors for becoming a trauma victim were studied with a special 
focus on socio-economy and comorbidity. Study II aimed to elucidate whether pre-traumatic 
treatment with β-blockers could be protective after severe trauma. In study III, the incidence 
of AKI and its relation to short and long-term mortality was examined among trauma patients 
treated in the ICU. In addition, risk factors for post-traumatic AKI were identified. In study 
IV, long-term mortality after trauma was analyzed and causes of excessive late death after 
trauma classified. 
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2 BACKGROUND 
2.1 EPIDEMIOLOGY 
Trauma is a leading cause of death and morbidity worldwide – the World Health 
Organization (WHO) estimate that more than five million individuals die each year as a result 
of injury. Injury thus accounts for almost 10 % of the world deaths and is the most common 
cause of death in individuals younger than 45 years of age in the Western world as well as in 
many of the developing countries. As an example, more than 200 000 individuals died from 
road traffic injuries in India 2013.1 Globally, approximately a quarter of the fatalities are 
caused by traffic-related accidents and another quarter by homicide and other intentional 
injuries.2,3 Among trauma-related deaths, WHO predicts that an increased proportion will be 
caused by road traffic injuries and falls in 2030 due to increased motorization and an aging 
population. This is supported by recent studies showing that patients admitted to trauma 
centers have become significantly older in the last decades.4,5 
In Sweden, 4867 individuals died from injuries in 2016. Hence, external causes were the third 
and sixth most common cause of death in men and women respectively.6 Although 
devastating, the millions of injuries with a fatal outcome only accounts for a small fraction of 
the injury burden to individuals and society. When comparing the impact on health using 
disability-adjusted life years (DALYs), the sum of years of life lost due to premature 
mortality and years lived with disability, injuries cause > 11 % of DALYs worldwide, placing 
it second only to cardiovascular diseases.7 
2.2 TRAUMA SCORING SYSTEMS 
There are several scoring systems in traumatology designed for classification of injuries, 
survival prediction and performance comparisons between centers. The Abbreviated Injury 
Scale (AIS) is an anatomical scoring system first published in 1971.8 The seven-digit AIS-
code specifies body region, specific structure, type and severity of injury. It is consensus-
derived and classifies each injury severity according to its relative importance on a six-point 
scale, where six indicate an injury not compatible with survival. AIS is currently the system 
of choice for injury data collection and has become the basis for a number of other scales in 
use. 
Injury Severity Score (ISS) is an anatomical description of injury that is designed to quantify 
the total load of anatomical injury across body regions. ISS is calculated by taking the sum of 
the squares of the AIS-codes for the most severe injury in each of the three most severely 
injured ISS body regions. The maximum score of ISS is 75. The body regions are divided 
into (1) head and neck, (2) face, (3) chest (thorax), (4) abdominal and pelvic contents, (5) 
extremities and bony pelvis and (6) external.9 An ISS above 15 is generally defined as major 
trauma or severe injury.10 
Mikael Eriksson 
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2.3 TRENDS IN TRAUMA CARE – ARE WE DOING BETTER? 
Several interventions have been shown to decrease mortality and improve outcome in the 
trauma setting. For example, the centralization of trauma care into centers with around-the-
clock availability of experienced and dedicated physicians has been shown to increase 
survival.11 Another aspect is the concept of hemostatic resuscitation and avoidance of 
traumatic coagulopathy. Although the exact ratio and timing of included components and 
monitoring of effects remain to be confirmed, the concept is probably beneficial in terms of 
reduced bleeding and increased survival.12-15 Moreover, the severely injured trauma patient is 
likely to benefit from general measures that have been shown to decrease mortality in the 
ICU such as lung-protective ventilation in severe Acute Respiratory Distress Syndrome 
(ARDS).16 
Treatments that are beneficial for the patient should be introduced, but of equal importance is 
the avoidance of harmful interventions. In the ICU for example, tight glucose control, 
administration of HES to septic patients and ventilation with large tidal volumes have all 
been shown to be harmful and should be avoided.16-18 
Short-term mortality among patients reaching hospital alive after trauma seems to decrease as 
an effect of these and other interventions.4,19,20 This trend, however, is counteracted by the 
significant increase in age of trauma patients in the last decades.4,20,21 
2.4 THE TRAUMA PATIENT’S JOURNEY – FROM HEALTH TO ILLNESS AND 
BACK AGAIN 
2.4.1 Risk factors for trauma occurrence 
Globally, males are twice as likely as females to die from injury and this difference is most 
apparent in individuals between 15-44 years of age.22 Men are also more prone to experience 
non-fatal injuries. Among patients admitted to the trauma unit and included in the Trauma 
Register at the Karolinska University Hospital, Stockholm more than two thirds are male.23 
Previous studies indicate that there is an association between residency in a region with lower 
socioeconomic status and an increased risk of traumatic events as well as death due to 
trauma.24-26 In addition, socioeconomic positions seem to increase the risk of experiencing 
trauma at an individual level.25,27,28 The reason for the variation in injury risk is probably 
multifactorial but not fully elucidated. Moreover, many studies on the association between 
socioeconomic factors and the risk of trauma have focused on specific mechanisms of injury 
such as road traffic incidents or self-harm.29 
Clinical experience and previous studies indicate a close connection between alcohol and 
trauma. Alcohol intoxicated individuals have a significantly increased risk of injury, with 
additional risk with higher alcohol intake in a dose-response pattern.30,31 Excessive long-term 
alcohol consumption increases the risk of trauma as well, with a similar dose-response 
effect.31 Efforts have been made to calculate the alcohol-attributable effect on trauma 
incidence. In a recent study by Cherpitel et al., including > 14000 patients from 18 countries 
Background 
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almost 17 % of all trauma cases in the emergency department were attributed to alcohol.32 In 
addition, previous studies suggest that a significant proportion of trauma patients are 
suffering from psychiatric disorders and substance abuse.33 Drug users have a known 
increased mortality compared to non-users, in part explained by traumatic deaths.34 Although 
findings from one specific region or specific centers might have reduced generalizability, a 
high prevalence of positive drug-tests has been noted in deceased trauma patients.35 
Moreover, there is a high and potentially increasing incidence of use and misuse of prescribed 
narcotics and benzodiazepines among victims of trauma.36 
The presence of somatic comorbidities increases the risk of fatal outcomes and complications 
after trauma but to what extent they contribute to the risk of trauma has not been fully 
elucidated.37-39 The strength of association between the presence of somatic comorbidities 
and outcome after trauma varies depending on definitions, case-mix, injury severity, age and 
follow-up.23 
In summary, many studies have investigated the association between specific socioeconomic 
positions or comorbidities and specific subgroups of injuries. Socioeconomic variables and 
comorbidities, however, are likely to be related and have not been analyzed together in 
previous studies in the trauma setting. 
2.4.2 The post-resuscitation phase – focus on organ failure 
Mortality in trauma research has since the influential work in the late seventies by Baker and 
Trunkey been classified as trimodal, based on the time elapsed from incident to death.40,41 
Immediate deaths on scene has mainly been attributed to unsurvivable injuries to the central 
nervous system, heart or large vessels. The majority of injury-related deaths still occur on 
scene or before arrival to the hospital.42 
Severe brain injuries and exsanguination are also the most common causes of early death 
within the first 48 hours in-hospital.43 The concept of a third “peak” of deaths within days to 
weeks after hospital admission, as described by Trunkey, does not seem to be accurate in 
modern trauma care where a continuous decline is a more accurate description.44-46 A 
significant proportion of post-traumatic deaths still occur in this phase where the most 
important causes of death are sepsis and multiple organ failure (MOF) in addition to 
traumatic brain injuries.43,44 
Individuals surviving the initial injury and the resuscitation phase including surgery are at 
high risk of later complications potentially altering the clinical course. MOF, ARDS, sepsis 
and AKI are known contributors to increased mortality and morbidity among the severely 
injured. Direct, traumatic lesions to the lungs, intestines, kidneys and other involved organs 
increases the risk of these conditions but the development of MOF is complex and not fully 
understood. The reaction to severe trauma seems to be similar to other causes of the Systemic 
Inflammatory Response Syndrome (SIRS), such as sepsis, with overwhelming activation of 
pro- and anti-inflammatory pathways and the coagulation system, glycocalyx degradation and 
endothelial damage and disturbed microcirculation.47-49 
Mikael Eriksson 
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The innate immune system can be activated by exogenous compounds from invading 
microorganisms (pathogen associated molecular patterns, PAMPs), or by endogenous 
molecules like S100-proteins and mitochondrial DNA (damage-associated molecular 
patterns, DAMPs) in the absence of infection. An excessive, systemic activation of the 
immune system and an imbalanced production of inflammatory factors are believed to cause 
organ dysfunction.47,48,50 Factors shown to be associated with subsequent MOF are age, ISS 
and other markers of injury severity, massive transfusion and coagulopathy, severe head 
injury and male gender.51-54 The risk of death increases with increasing number of failing 
organs.55 Improvements in the initial phases of trauma care may present more severely 
injured patients to the ICU, individuals that previously would not have survived (Figure 1). 
This, in combination with the increased age of admitted trauma patient might explain the 
increased incidence of MOF noted in some studies.53 
 
 
Figure 1. Median Injury Severity Score (ISS) per year for patients admitted to the Central-ICU or the 
Neuro-ICU at Karolinska University Hospital. 
 
2.4.2.1 β-blockade – protective? 
An established prophylaxis or targeted treatment for post-traumatic organ failure is lacking. 
In the last years, a proposed link between severe trauma and endothelial injury with 
subsequent coagulopathy, mediated through sympatho-adrenal hyperactivation has been 
presented (Figure 2).56 An increase in plasma catecholamines has been associated with 
markers of endothelial and glycocalyx damage, as well as signs of hypocoagulability.57 In this 
context, the administration of β-blockers to trauma patients seems to be a logic therapeutic 
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possibility to improve organ function and survival. Animal data indicate that administration 
of β-blockers might have anti-fibrinolytic and endothelial protective effects mediated via 
reduced sympathetic hyperactivity, thus suggesting a causal link.58 The positive results from 
β-blocker administration in sepsis, a condition with many similarities to severe trauma, 
further strengthen this hypothesis.59,60 
 
 
Figure 2. Shock-induced endotheliopathy (SHINE). Schematic illustration of the changes in the vascular 
compartment with increasing disease severity and increasing sympatho-adrenal activation. From Johansson et 
al., no changes made.56 Reprinted under Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/). 
 
Since traumatic coagulopathy occurs immediately, on the scene of accident, it is likely that 
endothelial damage and exposure of sub-endothelial structures is an early process as well.57,61 
Given that, having circulating levels of β-blockers in plasma already at the time of trauma 
might be protective. A few studies on the association between pre-traumatic β-blockade 
treatment and mortality have been presented with diverging results. In multiple trauma, 
studies have shown no difference or even increased mortality with β-blocker use whereas a 
protective effect has been noted in traumatic brain injury (TBI).62-66 
There are several plausible mechanisms for the absence of a protective effect in previous 
studies. First, a blunted hemodynamic response to injury with subsequent hypotension 
induced by β-blockers could have detrimental effects as previously shown.67 Secondly, 
imbalances in comorbidities at baseline might be difficult to adjust for in retrospective studies 
and the presence of significant comorbidities may have a profound effect on post-traumatic 
survival.5,37,38,63 
2.4.2.2 Acute kidney injury 
AKI is common among intensive care patients in general and among patients admitted with 
severe trauma, and closely associated with increased mortality.68-72 Studies suggest that AKI 
is a stronger predictor of fatal outcomes, such as multiple organ failure and death, among 
trauma patients than failure in other organ systems.73 The previous absence of a uniformly 
accepted definition of AKI has hampered research in the field of post-traumatic AKI but 
consensus definitions have been introduced in the last decades. In 2004 the Acute Dialysis 
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Quality Initiative introduced the first evidence-based consensus definition, the Risk, Injury, 
Failure, Loss, End-stage kidney disease (RIFLE) classification based on a relative increase in 
serum creatinine (sCr) compared to baseline or a decrease in urine output.74 The RIFLE 
criteria were modified into the Acute Kidney Injury Network (AKIN) classification in 2007 
with the aim of improving sensitivity.75 
In 2013 a new definition merging the RIFLE and AKIN criteria was proposed by the Kidney 
Disease Improving Global Outcomes (KDIGO) group (Table 1).76 Previous studies 
comparing the different criteria have yielded conflicting results but the KDIGO criteria might 
be a more robust predictor of outcome.77,78 
 
Table 1. Staging of AKI in adults according to KDIGO. 
Stage Serum creatinine Urine output 
1 1.5-1.9 times baseline* < 0.5 ml/kg/h for 6-12 hours 
 OR  
 ≥ 0.3 mg/dl (≥ 26.5 μmol/l) increase**  
2 2.0–2.9 times baseline < 0.5 ml/kg/h for ≥ 12 hours 
3 3.0 times baseline < 0.3 ml/kg/h for ≥ 24 hours 
 OR OR 
 Increase to ≥ 4.0 mg/dl (≥ 354 μmol/l) Anuria for ≥ 12 hours 
 OR  
 Initiation of renal replacement therapy  
* Known or presumed to have occurred within the prior 7 days. 
** Within 48 hours. 
 
AKI, defined by RIFLE or AKIN, following severe trauma has an incidence of 10-30 % 
varying with definitions and case mix.70,79,80 The risk of post-traumatic AKI is affected by 
patient factors, trauma-related factors and treatment factors. Regarding pre-traumatic 
characteristics, increased age is consistently associated with an increased risk of AKI. A 
higher prevalence of AKI is also noted in the presence of comorbidities such as obesity, 
diabetes mellitus and diseases of the cardiovascular system.70-72 
Increased injury severity, defined either by ISS or physiological derangement such as 
elevated lactate or base deficiency, is closely linked to subsequent AKI.72,79-81 Although 
uncommon, direct lesions to the kidneys or the urinary tract can lead to reduced kidney 
function following injury.82 Much focus in trauma research in the last decade has been 
towards resuscitation strategies including reduced amounts of crystalloids and the 
administration of high ratios of fresh frozen plasma and platelets to red blood cells in the 
Background 
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bleeding patient. The aim of this damage control resuscitation is to prevent the development 
of acute traumatic coagulopathy and to optimize oxygen delivery capacity. This approach 
seems to reduce the number of deaths due to exsanguination and might improve overall 
survival.14,83 In contrast, blood product administration has been associated with increased risk 
of post-traumatic AKI.71,79 
There has been much concern regarding the administration of artificial colloids to critically ill 
patients and an increased risk of AKI, with particular focus on HES that has been 
convincingly associated with AKI among patients with sepsis.18,84,85 In the trauma setting, 
older compositions with larger starch-molecules and higher-molar substitutions such as HES 
450/0.7 have been associated with AKI in retrospective studies.86,87 On the contrary, a single-
center RCT found that administration of HES 130/0.4 was associated with a lower incidence 
of AKI among patients with penetrating trauma compared to 0.9 % saline.88 
2.4.3 Long-term outcomes 
Trauma outcome has traditionally been measured in a short-term perspective as in-hospital or 
30-day mortality, a recommended endpoint in trauma registers and research in Europe.89 
However, several studies on long-term outcome indicate that short-term mortality poorly 
reflects the overall mortality attributed to trauma. When compared to the background 
population, or a matched comparison group, trauma patients seem to have a significantly 
increased mortality in several years following trauma.90-94 This increase in long-term 
mortality may counterbalance the improvements in short-term outcome, i.e. in-hospital 
mortality decreases but overall mortality remains unchanged.93 
Although the increased late mortality in this group of patients is significant and seems 
consistent across the western world, few studies have investigated the causes of late death. In 
a study from Baltimore the most common causes of late death were external causes, such as 
new trauma or intoxication, being responsible for almost 40 % of post-discharge deaths.95 
Not surprisingly, diseases of the circulatory system were the most common somatic cause of 
death. These results must be generalized with caution due to the extremely high proportion of 
intentional violence (56 %) and penetrating injury (43 %) in the study cohort. Another US 
study reported that one third of post-discharge deaths were attributed to trauma.96 In the only 
European data published, external causes and diseases of the circulatory system were the 
most common causes of late death following trauma.92 Thus, late death after trauma appears 
to be a substantial but underestimated problem. 
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3 AIMS OF THE THESIS 
To examine the influence of socioeconomic factors and comorbidity on the risk of becoming 
a trauma victim. 
To investigate whether pre-traumatic β-blocker therapy could be protective after severe, 
multiple trauma. 
To analyze the incidence of post-traumatic AKI and the long-term effects regarding survival 
and end-stage renal disease among trauma patients treated in the ICU. 
To identify patient-related and modifiable factors associated with post-traumatic AKI. 
To evaluate increased long-term mortality among trauma victims and identify causes of 
excess late mortality. 
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4 MATERIALS AND METHODS 
 
4.1 NATIONAL REGISTERS 
The unique, 12-digit personal identity number provided to all Swedish citizens allows linkage 
of patient data to national and regional registers.97 
4.1.1 The Register of Total Population 
Statistics Sweden (SCB) is responsible for the Register of Total Population since its 
establishment in 1968. The register holds information on national registration, marital status, 
citizenship etcetera and is subsequently providing information to other registers.98 
4.1.2 The Longitudinal Integration Database for Health Insurance and 
Labour Market Studies (LISA) 
The LISA-register is linked to several other national registers and holds information on 
individuals of age 16 or older. It is run by SCB and provides individual information on 
employment, income and highest achieved education in addition to other socio-economic 
variables.99 It has been annually updated since 1990. 
4.1.3 The National Patient Register 
Starting out in a small-scale in 1964, and subsequently expanded, The National Patient 
Register is managed by the Swedish National Board of Health and Welfare (NBHW). It 
contains information on all in-patient care episodes in psychiatric care since 1973 and in 
somatic care since 1987. Specialized outpatient care, i.e. not primary care, is included from 
2001. The initial coverage for outpatient care was below 75 % regarding the main diagnose in 
the first years but has improved over time and is now considered to be > 95 %.100,101 
Each care episode is registered with data on personal identity number, hospital or clinic and 
admission and discharge dates. Diagnosis, of which one is principal, is listed according to 
International Classification of Diseases (ICD) coding. ICD version 10 has been used in 
Sweden since 1997. 
4.1.4  The Cause of Death Register 
The Cause of Death Register, managed by NBHW, contains data from 1961 and onwards. All 
deceased Swedish citizens are included, regardless of place of death.102 In addition, from 
2012 all deaths occurring in Sweden are included regardless of national registration for the 
individual. The physician that determines death is responsible that a cause of death report is 
submitted to NBHW. According to WHO standards the cause of death is registered according 
to ICD-10 codes. The immediate cause of death, i.e. the final disease or condition that 
resulted in death is registered as primary cause of death. The conditions that lead up to the 
Mikael Eriksson 
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primary cause of death is subsequently listed, with the underlying cause of death defined by 
WHO as “the disease or injury which initiated the train of morbid events leading directly to 
death, or the circumstances of the accident or violence which produced the fatal injury”.103 
The coverage is considered excellent with < 1 % loss of death certificates. Misclassifications 
of the underlying cause of death have been estimated to approximately 20 % overall but vary 
with age and diagnose groups. It is considered to be lower among younger individuals and in 
patients with violent causes of death, malignancies and ischemic heart disease.104 
4.1.5 The Prescribed Drug Register 
The Prescribed Drug Register contains information on all prescribed drugs dispensed at 
pharmacies in Sweden. It is managed by the NBHW and the addition of personal identity 
numbers on July 1st 2005 made linkage to other registers possible from that date. It is 
considered to have 100 % coverage regarding dispensed drugs. Medications administered in 
hospitals and some nursing homes are not included, there are also some missing data on drugs 
administered in day-care such as biologic drugs against rheumatoid arthritis and cancer 
treatments.105-107 
 
4.2 REGIONAL REGISTERS 
The relationship between regional registers are presented in Figure 3. 
 
Figure 3. Flow chart of the relation between regional trauma registers. 
Materials and methods 
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4.2.1 Trauma Register Karolinska 
All patients admitted with full trauma team activation have been included in the Trauma 
Register of the Karolinska University Hospital since 2005. It holds information on pre-
hospital as well as in-hospital care, admission time, trauma mechanism, physiological 
derangement and outcome variables. Patients admitted without full trauma team activation 
but retrospectively found to have injuries with an ISS of > 9 are also included. Patients with 
severe burns or hypothermia without other traumatic injuries, chronic subdural hematomas or 
isolated fractures of the extremities are not included. The Trauma Register Karolinska reports 
data to the Swedish Trauma Register (SweTrau) from 2013 and data are registered according 
to the Utstein Template from the same year.89 
4.2.2 The Intensive Care Unit Register 
From February 2007, trauma patients age 15 or older with an expected ICU stay of more then 
24 hours admitted to the Central ICU at the Karolinska University Hospital are included in a 
database. Research nurses collect detailed information on organ failure, specific treatment 
and outcome variables daily. Data are verified twice to ensure quality and pre-hospital and 
baseline data are added retrospectively from the Trauma Register Karolinska. Data collection 
continues until discharge from the ICU or death. 
4.3 DEFINITIONS 
Education was categorized from the highest achieved level in the year of trauma as low, 
medium or high corresponding to ≤ 9, 10 - 12 or > 12 years of schooling respectively. Thus, 
high education equals university level in the Swedish school system. Income was classified as 
low, medium or high corresponding to < 50 %, 50 - 200 % or > 200 % of the median income 
in Sweden the year preceding trauma. Comorbidities were extracted from the Patient Register 
(Paper I, II and IV) and from patient charts (Paper III). Somatic comorbidity was defined as 
the presence of any of the somatic diagnosis included in the Charlson Comorbidity Index 
(CCI) up to eight years prior to trauma (Paper I and IV) and analyzed individually as 
specified in Paper II. In Paper III diabetes mellitus was extracted from the CCI and analyzed 
as a separate entity. The CCI was coded from ICD-10 as previously described.108,109 
Psychiatric comorbidity and substance abuse were defined as the presence of any of ICD-10 
codes F20-F99 and F10-F19 respectively. 
4.4 STATISTICS 
Data are in general presented as count (%) or median with interquartile range (IQR) as 
depicted in tables. Continuous variables were considered non-normally distributed and 
compared with Mann-Whitney U test or Kruskal-Wallis test as appropriate. Proportions were 
compared with χ2-test or Fisher’s exact test depending on sample size and frequency 
distribution. Differences in survival in Paper II-IV were compared with log rank test. 
Differences in survival over specific time intervals in Paper IV were calculated from deaths 
per person-time in each group, as mortality rate ratios (MRR) with corresponding 95 % 
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confidence intervals (CI). Predictors of trauma risk in Paper I were analyzed with logistic 
regression analysis conditional on matched group. Adjustment for confounders in Paper II 
and risk factor analyses in Paper III was performed with multivariable logistic regression. 
Results from regression analyses are presented as odds ratios (OR) with 95 % CI. Data was 
analyzed as complete cases (Paper I and III) and as complete cases and with multiple 
imputations (MI) (Paper II). Hosmer-Lemeshow test was used to analyze model 
performances. P < 0.050 was considered statistically significant, all tests two-tailed. IBM 
SPSS Statistics version 21.0 and 22.0 (IBM, Armonk, NY, USA), Stata/SE 14.2 (StataCorp, 
College Station, TX, USA) and GraphPad Prism version 6.0 (GraphPad Software, La Jolla, 
CA, USA) were used for statistical analyses. 
4.5 STUDY DESIGN AND OUTCOME MEASURES 
Study design and outcome measures are summarized in Table 2. 
Table 2. Study design and outcome measures. 
Study I II III IV 
Design Case-control Cohort study Cohort study Matched cohort study 
Study population Prospectively 
collected trauma 
cohort 2005-2010 
Prospectively 
collected trauma 
cohort 2005-2015 
ICU-treated trauma 
patients Feb. 2007-
Sept. 2012 
Prospectively 
collected trauma 
cohort 2005-2010 
Sample size Cases 7382 
Controls 36760 
1376 413 Patients 7382 
Controls 36759 
Register used Trauma Register 
Patient Register 
LISA 
Register of Total Pop. 
Trauma Register 
Patient Register 
LISA 
Register of Total Pop. 
Cause of Death 
Register 
Prescribed Drug 
Register 
Trauma Register 
Intensive Care Unit 
Register 
Trauma Register 
Patient Register 
Register of Total Pop. 
Cause of Death 
Register 
Follow up - 30 days 1 year Min. 1 year, mean 3.5 
years 
Outcome measures Event: Trauma 
Exposure: 
socioeconomic 
factors, comorbidity 
Association between 
pre-traumatic β-
blockade and 
mortality 
Incidence of AKI, risk 
factors for AKI, 30-
day and one year 
mortality 
MRR, causes of late 
death beyond 30 days 
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4.5.1 Study I 
In a case-control study, injured patients from the Trauma Register Karolinska between 2005-
2010 (cases) were matched by age, gender and municipality in a 1:5-ratio to uninjured 
individuals from the Register of Total Population (controls). Baseline data on income and 
education were extracted from LISA and data on comorbidities from the Patient Register. The 
relative importance of socio-economic status and comorbidities on trauma risk was explored 
with regression analysis. The time-dependency of included comorbidities was evaluated by 
analyzing a more recent (< 6 months prior to trauma) diagnosis separately. 
4.5.2 Study II 
Patients from the Trauma Register Karolinska 2006-2015, age > 50 and ISS > 15 were 
extracted and included in a cohort study. Patients not expected to survive regardless of 
treatment, defined as ISS = 75, were excluded. Patients were linked to LISA and the Patient 
Register, thus providing baseline data on socio-economy and comorbidity. Individuals were 
also linked to the Prescribed Drug Register to define β-blocker use at the time of trauma. The 
association between pre-traumatic β-blocker use and 30-day mortality was explored using 
multivariable logistic regression with adjustment for important baseline imbalances, 
comorbidities and trauma-related factors. 
4.5.3 Study III 
Patients included in the ICU Register from February 2007 - September 2012 were analyzed in 
a cohort study. The outcome measure was AKI according to the KDIGO classification 
occurring day 2 - 7 after admittance.76 Individuals that died before day two and those with a 
known chronic kidney disease were excluded. The patients were followed for one year with 
respect to survival and end-stage kidney disease. Logistic regression analysis was used to 
identify factors associated with AKI occurrence. 
4.5.4 Study IV 
All injured patients from the Trauma Register Karolinska 2005-2010 were matched by age, 
gender and municipality in a 1:5-ratio to uninjured controls from the Register of Total 
Population. Socio-economic variables and comorbidity were assessed by linkage to LISA and 
the Patient Register, and cause of death by linkage to the Cause of Death Register. The cause 
of death was defined as the immediate cause of death noted in the cause of death certificate. 
In a matched cohort study long-term mortality was compared with MRR for specific time-
periods between injured and uninjured individuals up to three years after the index trauma. 
Causes of death were compared within the trauma cohort, stratified by time to death, and 
between the trauma cohort and the control group. 
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5 RESULTS 
5.1 STUDY I 
7382 trauma patients (cases) and 36760 controls were included. Compared to the controls, 
fewer trauma patients had achieved university level of education or had high income. All 
included comorbidities were more common among trauma patients. These differences were 
unchanged when restricting the analysis to the most severely injured group (ISS > 15). The 
distribution of injury mechanisms differed between categories of education and income. 
Assault was three times more common among those with a low level of education and almost 
four times more common among those with low income, compared to those with the highest 
education and income. 
In the conditional logistic regression analysis both level of education and income, and all 
included comorbidities (somatic, psychiatric and drug abuse) were significantly associated 
with the risk of trauma. This association was unchanged when analyzing the most severely 
injured separately, except from somatic comorbidity no longer being a risk factor (Table 3). 
 
Table 3. Conditional logistic regression analysis of level of education, income and comorbidity as risk factors 
for trauma. Odds ratios with 95 % confidence interval. Analysis of all patients and stratified for injury severity 
(ISS > 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 Odds Ratio (95 % CI) Odds Ratio (95 % CI) 
 All ISS >15 
 unadjusted adjusted unadjusted adjusted 
Level of education 
    
     Low  1.8 (1.7-1.9) 1.5 (1.4-1.6) 1.7 (1.5-1.9) 1.4 (1.2-1.6) 
   Medium  1.5 (1.4-1.5) 1.3 (1.3-1.4) 1.5 (1.3-1.7) 1.3 (1.1-1.5) 
   High  1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Income     
    Low 1.8 (1.6-2.0) 1.2 (1.1-1.3) 2.0 (1.6-2.6) 1.3 (1.1-1.7) 
    Medium 1.5 (1.3-1.6) 1.2 (1.1-1.4) 1.7 (1.3-2.2) 1.4 (1.1-1.8) 
    High  1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
Comorbidity     
    Psychiatric diagnosis 2.1 (2.0-2.3) 1.5 (1.4-1.6) 2.1 (1.8-2.4) 1.4 (1.2-1.6) 
    Substance abuse diagnosis  3.3 (3.1-3.5) 2.6 (2.4-2.8) 3.9 (3.4-4.4) 3.4 (3.0-4.0) 
    Somatic diagnosis 1.3 (1.2-1.3) 1.1 (1.1-1.2) 1.2 (1.1-1.3) 1.0 (0.9-1.1) 
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The analysis for time dependency showed that a recent diagnosis, i.e. within 6 months, of 
substance abuse or somatic disorders increased the risk of trauma significantly (Figure 4). 
 
 
Figure 4. Impact of treatment for psychiatric comorbidity, substance abuse or somatic disorder within six 
months on the risk of trauma. The figure displays how the adjusted odds ratio (95% confidence interval) for 
trauma is affected by having the most recent treatment within six months (closed circles) as compared with 
before six months (open triangles) at the time of injury for all and severely injured (ISS > 15) patients 
respectively. All analyzes adjusted for socio-economic status. 
 
Psychiatric diagnosis
1 50.5
< 6 months
> 6 months
Odds ratio
All
ISS >15
Substance abuse
1 50.5
Odds ratio
All
ISS > 15
Somatic diagnosis
1 50.5
Odds ratio
All
ISS > 15
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5.2 STUDY II 
1376 severely injured patients, age > 50 were included in the final analysis. Of these, 338 
(24.6 %) received β-blockers at the time of trauma. There was no significant difference in 
injury severity between β-blocker users and non-users. The first recorded blood pressure was 
similar and patients from both groups expressed shock on arrival and were treated in the ICU 
to the same extent (Table 4). 
 
Table 4. General characteristics and clinical outcome in the study cohort stratified 
by β-blocker therapy. 
 β-blocker (-) β-blocker (+) p 
Count (%) 1038 (75.4) 338 (24.6)  
Age, median (IQR) 63.5 (56-73) 71.5 (63-82) < 0.001 
Male, count (%) 733 (70.6) 223 (66.0) 0.108 
Education level, count (%) 
    Low 
    Medium 
    High 
 
240 (25.1) 
444 (46.3) 
274 (28.6) 
 
88 (30.6) 
125 (43.4) 
75 (26.0) 
0.175 
CCI, median (IQR) 0 (0-1) 1 (0-2) < 0.001 
Ischemic heart disease, count (%) 27 (2.6) 96 (28.4) < 0.001 
Congestive heart failure, count (%) 28 (2.7) 60 (17.8) < 0.001 
Hypertension, count (%) 118 (11.4) 141 (41.7) < 0.001 
Diabetes mellitus 69 (6.6) 62 (18.3) < 0.001 
Anticoagulation therapy  31 (3.0) 65 (19.2) < 0.001 
Psychiatric comorbidity, count (%) 142 (13.7) 39 (11.5) 0.312 
Substance abuse, count (%) 172 (16.6) 48 (14.2) 0.302 
ISS, median (IQR) 24 (17-27) 25 (17-26) 0.911 
Blunt trauma, count (%) 1020 (98.3) 331 (97.9) 0.689 
Severe head injury, count (%) 651 (62.7) 216 (63.9) 0.694 
Severe thoracic injury, count (%) 400 (38.5) 132 (39.1) 0.865 
Severe abdominal injury, count (%) 89 (8.6) 28 (8.3) 0.868 
SAP*, median (IQR) 144 (120-164) 150 (120-170) 0.073 
SAP* < 90 mm Hg, count (%) 83 (8.0) 32 (9.5) 0.396 
ICU admittance, count (%) 602 (58.0) 190 (56.2) 0.565 
30-day mortality, count (%) 205 (19.7) 111 (32.8) < 0.001 
 
Continuous parameters presented as median with interquartile range (IQR), categorical parameters as 
n (%). CCI, Charlson Comorbidity Index; ISS, Injury Severity Score; SAP, Systolic Arterial Pressure; ICU, 
Intensive Care Unit. *On arrival to the trauma unit. 
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Of all included patients, 316 (23.0 %) died within 30 days. β-blocker users had a significantly 
higher crude mortality than non-users, 32.8 % vs. 19.7 % (p < 0.001, log-rank test) (Figure 5). 
 
 
 
 
Figure 5. 30-day survival of patients categorized as β-blocker users (β-blocker(+)) or non-users (β-blocker(-)). 
 
In univariate regression analysis, patients treated with β-blockers had increased odds of death, 
OR 1.99 (95 % CI 1.51-2.61, p < 0.001). When adjusted for baseline imbalances and injury-
related factors this association was no longer significant, OR 1.09 (0.70-1.70, p = 0.703) 
(Table 5). There were no significant interactions between β-blocker use and head injury or β-
blocker use and shock on arrival. When analysed separately, there was no significant 
association between pre-traumatic β-blockade and mortality for individuals with or without 
severe head injury respectively. 
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OR, Odds Ratio; CI, Confidence Interval; MI, Multiple imputations. 
* Restricted model: adjusted for age, gender, injury severity, severe head injury and shock on arrival. 
** Full model: in addition to the restricted model adjusted for education, ischemic heart disease, congestive 
heart failure, hypertension, diabetes mellitus and anticoagulation therapy. 
*** Full model with multiple imputations of missing data for education. 
  
Table 5. Associations between pre-injury β-blocker use and 30-day mortality, unadjusted and adjusted odds ratio 
(95 % confidence interval). 
 OR (95 % CI) p-value 
Unadjusted  1.99 (1.51-2.61) < 0.001 
Restricted model* 1.35 (0.96-1.90) 0.085 
Full model** 1.09 (0.70-1.70) 0.703 
Full model, missing data analysed with MI*** 1.09 (0.73-1.61) 0.675 
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5.3 STUDY III 
After exclusion of individuals that died before the start of the study period and those with 
known chronic kidney disease, 413 patients were included in the analysis. The median age in 
the whole cohort was 40 years, 78 % were male and the vast majority (89 %) presented with 
blunt trauma. Overall mortality was 8.7 % at 30 days and 11.9 % at one-year post injury. 
Baseline data for patients with and without AKI are shown in Table 6. 103 patients (24.9 %) 
developed AKI. KDIGO stages 1, 2 and 3 were noted in 59 %, 13 % and 28 % of AKI 
patients respectively. 27 patients were treated with continuous renal replacement therapy 
(CRRT) but none of the survivors were dialysis dependent at three months or one-year 
follow-up. 
 
Table 6. Baseline characteristics and clinical outcome for patients with and without AKI 
 non-AKI AKI p 
Count (%) 310 (75.1) 103 (24.9)  
Age, years, median (IQR) 36 (25-51) 54 (36-69) 0.000 
Male, count (%) 233 (75.2) 89 (86.4) 0.017 
Non-diabetic comorbidity, count (%) 31 (10.0) 24 (23.3) 0.001 
Diabetes mellitus, count (%) 9 (2.9) 11 (10.7) 0.001 
ISS, score, median (IQR) 24 (17-33) 29 (19-43) 0.000 
Blunt trauma, count (%) 273 (88.1) 95 (92.2) 0.239 
Admission SAP < 90 mm Hg, count (%) 40 (12.9) 27 (26.2) 0.002 
Admission GCS, score, median (IQR) 14 (8-15) 11 (7-15) 0.005 
Massive transfusion, count (%) 39 (12.6) 36 (35.0) 0.000 
Fluid load 24 hours, L, median (IQR) 5.8 (4.0-8.5) 8.6 (5.3-13.9) 0.005 
HES, L, median (IQR) 0.5 (0-1.0) 1.0 (0-1.5) 0.000 
HES administered, count (%) 177 (57.1) 74 (71.8) 0.008 
Sepsis, count (%) 75 (24.2) 47 (45.6) 0.000 
Renal replacement therapy, count (%) 0 (0.0) 27 (26.2) 0.000 
ICU length of stay, days, median (IQR) 3.0 (2.0-6.0) 10.0 (4.3-17.0) 0.000 
30-day mortality, count (%) 18 (5.8) 18 (17.5) 0.000 
Continuous parameters presented as median (interquartile range, IQR), categorical parameters as count and %. 
ISS, Injury severity score; SAP, systolic arterial pressure; GCS, Glasgow coma scale; HES, hydroxyethyl starch. 
Admission refers to the admission to the trauma unit. 
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AKI was significantly associated with increased mortality at 30 days and after one year 
(Figure 6). 
 
 
 
Figure 6. Kaplan-Meier survival curve for one-year post-injury survival for patients with AKI (n = 103, red line) 
and without AKI (n = 310, blue line).  
 
 
 
In univariate logistic regression analysis male gender, age, diabetes mellitus, non-diabetic 
somatic comorbidity, ISS > 40, massive transfusion, administration of HES, sepsis and shock 
on arrival (SAP < 90 mmHg on arrival to the trauma unit) were all significantly associated 
with post-traumatic AKI. In the multivariable model all variables except sepsis and shock 
remained independent risk factors for AKI (Figure 7). 
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Figure 7. Multivariable associations for AKI risk, odds ratio and 95 % confidence interval. ISS, 
injury Severity Score; HES, hydroxylethyl starch; AKI, acute kidney injury; SAP, systolic 
arterial pressure. 
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5.4 STUDY IV 
7382 patients and 36759 matched controls were included, general characteristics are 
presented in Table 7. 
Table 7. General characteristics of the study cohort and control group. 
 Trauma patients Controls  
n 7382 36759  
Gender, n (%)    
   Female 2297 (31.1) 11436 (31.1)  
   Male 5085 (68.9) 25323 (68.9)  
Age    
   Median (IQR) 39 (25-55) 39 (25-55)  
Comorbidity, n (%) 2869 (38.9) 9115 (24.8)  
   Psychiatric 989 (13.4) 2017 (5.5)  
   Substance abuse 1029 (13.9) 1053 (2.9)  
   Somatic 1805 (24.5) 7142 (19.4)  
Mechanism of injury, n (%)    
   Traffic related 3926 (53.2)   
   Fall 2087 (28.3)   
   Assault 829 (11.2)   
   Self inflicted 267 (3.6)   
   Others 271 (3.7)   
Violence, n (%)    
   Blunt 6914 (93.7)   
   Penetrating 468 (6.3)   
ISS    
   Median (IQR) 5 (2-14)   
   ISS >15, n (%) 1764 (23.9)   
Mortality, n (%)    
   30-days 370 (5.0) 30 (0.1)  
   1-year 526 (7.1) 317 (0.9)  
   3-year 662 (9.0) 796 (2.2)  
   Total follow-up 755 (10.2) 1089 (3.0)  
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The overall mortality rate was significantly increased over the study period in the trauma 
cohort compared to the control group (Figure 8). 
 
 
 
  
Figure 8. All cause mortality rate ratio with 95 % confidence interval for injured patients versus non-injured 
controls. 
 
 
For trauma patients the most common causes of late death were diseases of the circulatory 
system and external causes. Neoplasms and diseases of the circulatory system were the most 
frequent causes of death in the control group. Trauma patients were more likely to die from 
an external cause of death and less likely to die from neoplasms than individuals in the 
control group (Figure 9a). When comparing late trauma deaths occurring before and after 
discharge, patients who died while still in hospital were more likely to die from respiratory 
causes whereas patients deceased after discharge were more likely to die from neoplasms and 
diseases of the circulatory system (Figure 9b). 
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Figure 9. Proportions of late death by cause, classified according to ICD-10: a for injured patients who died 
between days 31 and 365 or more than 365 days after index trauma, compared with controls; b before and 
after discharge for injured patients. *P < 0.050 (any difference between all three groups in a, versus after 
discharge in b). 
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There were different distributions of age, comorbidities and injury severity between survivors 
and non-survivors of trauma. Patients with an external cause of death had a very high 
prevalence of psychiatric co-morbidity and substance abuse (Table 8). 
 
Table 8. Characteristics of patients who died more than 30 days after the index trauma 
compared with trauma survivors. 
 Non-survivors Survivors p 
 External cause of death Non-external cause of death   
n 72 313 6627  
Gender, n (%)     
   Female 17 (23.6) 95 (30.4) 2070 (31.2) 
0.364 
   Male 55 (76.4) 218 (69.6) 4557 (68.8) 
Age, median (IQR) 52 (36-61) 70 (56-83) 37 (24-51) < 0.001 
Comorbidity, n (%) 53 (73.6) 248 (79.2) 2332 (35.2) < 0.001 
   Psychiatric 27 (37.5) 51 (16.3) 858 (12.9) < 0.001 
   Substance abuse 31 (43.1) 70 (22.4) 872 (13.2) < 0.001 
   Somatic 22 (30.6) 219 (70.0) 1371 (20.7) < 0.001 
ISS     
   Median (IQR) 14 (5-25) 10 (5-17) 5 (2-13) < 0.001 
   ISS >15, n (%) 35 (48.6) 110 (35.1) 1308 (19.7) < 0.001 
Continuous parameters presented as median with interquartile range (IQR), categorical parameters as 
n (%). ISS, Injury Severity Score. 
 
 
Late death due to suicide was almost nine times more common among patients with a self-
inflicted trauma than in patients with other mechanisms of injury. In addition, suicide was 
four times more common among injured patients who were discharged alive compared to 
matched controls. A detailed analysis of post-discharge death from external causes among 
the injured patients showed that the majority was due to a new trauma or substance 
abuse/intoxication, including suicide (Figure 10). 
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Figure 10. Proportion of late deaths after discharge from external causes according to ICD-10. Hatched 
shading indicates proportion caused by suicide 
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study design 
All included studies in this thesis are observational, epidemiological studies that in general 
are considered to be of a lower evidence grade than the most common type of experimental 
clinical study, the randomized controlled trial. However, if well performed observational 
studies with contemporaneous controls may produce results very similar to results from 
prospective randomized controlled trials.110,111 Moreover, some clinical questions could 
obviously never be answered by prospective randomization due to lack of equipoise or for 
ethical reasons. The association between pre-traumatic β-blockade and outcome after trauma 
is one example. 
Study I was a case-control study, in general preferred when the outcome of interest is rare.112 
Study II and III were cohort studies with patients extracted from two different local registers, 
whereas study IV was a matched cohort study with long-term follow up. As previously stated, 
trauma is a comparatively common cause of death in Sweden. However, admittance with 
severe injuries to a designated trauma center is a rare outcome from an epidemiologic 
perspective. 
An alternative approach to the case-control design in Study I and the cohort design based on 
local registers in Study II and IV, would have been to solely use the national registers in 
Sweden, with traumatic injuries defined from ICD-coding.113,114 However, patients admitted 
to trauma centers are different from patients admitted to regular emergency departments, 
partly due to different mechanisms of injury. There is an accumulation of motor vehicle 
incidents, assault and high-energy falls and less sports-related injuries and fractures after falls 
from low levels.11 Thus, these patients are considered an entity of their own, and using the 
trauma register enables comparison to other studies within the research field. Moreover, 
although injury severity can be classified on the basis of ICD-codes, access to extensive 
original data may have reduced the risk of misclassification of outcome in Study I and 
provided more precise adjustments for confounders in Study II. 
6.1.2 Generalizability 
In general, studies are performed to make inferences regarding the population from which the 
study sample is drawn. The included studies represent the experiences from a single center in 
northern Europe which of cause may reduce the generalizability and the possibility to draw 
general conclusions. The Swedish healthcare system, where all trauma patients are treated in 
the public sector and health care in general is tax-funded, differs from other parts of the 
world. In addition, the associations between socioeconomic status and trauma risk in study I 
may be different in countries with lower income or a younger population. 
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Stating that, the patients included in the studies based on the trauma register (Study I, II and 
IV) are very similar to other comparable studies regarding baseline characteristics, 
comorbidity and type of violence.11,37,38,115 
Inclusion and exclusion criteria in registers and studies are of utmost importance for the 
ability to extrapolate study results to other contexts; in the trauma setting injury severity is of 
particular interest. The trauma cohorts in study I and IV were on average moderately injured 
with a median ISS of 5. Restricting the analyses to the most severely injured did not change 
the associations significantly, suggesting that our results are generalizable in this aspect. 
In Study II, only individuals age 50 or older were included. Thus, we cannot conclude that β-
blockade could not be beneficial, or detrimental, among younger individuals. In study III, 
individuals with a known history of chronic kidney disease were excluded, making inferences 
on this subgroup impossible. Another aspect is timing of AKI diagnosis, in our material 
limited from day two to day seven after admission, which may have implications when 
compared to studies with different timeframes.70,79 
6.1.3 Misclassification 
6.1.3.1 Misclassification of exposure 
There are many potential sources of misclassification of exposure in epidemiological 
research; quality of data, definitions of exposure variables and categorization of continuous 
variables are among them. 
Three of the included studies (I, II and IV) use national registers for ascertainment of 
exposure and comorbidity classification. The information provided from LISA regarding 
income and education is considered robust, however, missing data was noted for 9 % of the 
patients regarding education and 5 % regarding income. The patient register does not include 
information from primary care and the outpatient part had incomplete coverage during the 
first years. Thus, we cannot rule out misclassification of individuals with comorbidities of 
minor severity. The unchanged results regardless of comorbidity definition in Study II, and 
previous experiences from the research group, suggest that this may be of minor importance. 
The definition of users and non-users of β-blockers is essential in Study II. Previous studies 
suggest that register-based classification of users is valid, especially regarding chronic 
medications and cardiovascular drugs.116-120 In support of this is the unchanged result in the 
sensitivity analysis with different definitions of users. Another aspect is that the majority of 
deaths after traumatic injuries occur on-stage, or before admittance to trauma centers.42 If 
those deceased pre-hospital were more or less likely to use β-blockers is unknown. They were 
however unlikely to survive regardless of treatment and this is considered a minor problem in 
Study II but may affect estimates in Study I. 
Of particular interest in study III is the definition of sepsis, since sepsis is one of the most 
important causes of AKI in the ICU-setting. Sepsis has been defined as the combination of 
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suspected or proved infection and physiologic signs of systemic inflammation in response to 
the infection. Separating injury-related from infectious-related physiologic derangement 
could be difficult.121-123 Although efforts have been made to ascertain the presence of 
infection in the register, we cannot rule out that SIRS in some patients classified as septic was 
caused by trauma or surgery instead of infection. This might be an explanation to the 
somewhat unexpected lack of association between sepsis and subsequent AKI. 
6.1.3.2 Misclassification of outcome 
The Swedish Cause of Death Register has almost 100 % coverage, and death per se as an 
outcome is considered robust. The underlying cause of death has been estimated to be 
approximately 80 % correct.104 It is considered more accurate among younger individuals and 
for specific diagnosis, e.g. violent causes of death. In study IV the immediate cause of death 
was used, the validity of this variable is unknown but represents the best possible assessment 
from the responsible physician. The underlying cause of death is of utmost importance for 
society and stakeholders and to guide preventive efforts. It is, however, difficult to use in 
register-based trauma studies since a vast majority of patients will have trauma as the 
underlying cause of death regardless of clinical course and complications. 
The diagnosis of AKI, regardless of definition, is problematic and prone to errors, which may 
have implications for Study III. The most recent definition, the KDIGO staging, is based on 
markers of renal function, i.e. glomerular filtration, and not kidney-cell injury. The relative 
increase in sCr or decrease in urinary output could for example be caused by hypovolemia or, 
in the trauma setting, under-resuscitation or direct muscle injury without subsequent kidney 
injury.80 This issue was addressed by not diagnosing AKI prior to day two. In addition, the 
biochemical diagnosis of AKI is based on a relative increase in sCr compared to the baseline 
value, a variable missing in this data set as well as in many others. A common way to address 
this shortcoming is to impute baseline sCr by back-calculation using the Modification of Diet 
in Renal Disease (MDRD) equation assuming a low normal glomerular filtration rate of 75 
mL/min per 1.73 m2.70 This approach might lead to both overestimation and underestimation 
of AKI, especially of its milder forms.124 
In study III, baseline sCr was defined as the lower value of the MDRD-imputed sCr or the 
lowest measured sCr within 24 hours after admission to the hospital. Despite the inherent 
problems with baseline sCr, a markedly elevated mortality in the AKI-group compared to 
non-AKI patients was observed, supporting the validity of the AKI classification. Techniques 
such as MI could be an even better approach to solve this issue.125 
6.1.4 Confounding 
Confounders are by definition factors related to both exposure and outcome, and in opposite 
to intermediate factors not on the causal pathway between them. Confounders can be handled 
in the design of the study by randomization, matching or restriction. They can also be 
addressed in the analysis phase, for example in regression analysis or with stratification. 
Mikael Eriksson 
36 
6.1.4.1 Study 1 
The purpose of a control group in a case control study is to estimate the exposure in the 
population that provides the cases. Matching in case control studies, or any nonrandom 
sampling, could thus introduce bias since the controls might differ from the entire population 
from which they were drawn regarding exposure. This was addressed in the analysis phase 
with conditional logistic regression, keeping the matched groups together. Included patients 
were also stratified by injury severity. 
6.1.4.2 Study II 
The study cohort was restricted regarding age and injury severity. Baseline imbalances 
between β-blocker users and non-users were adjusted for with multiple logistic regression 
including known and suspected confounders. Missing data was addressed with MI. A 
propensity score matched data set could have been an alternative but might have produced 
other problems such as an atypical control group.126,127 
6.1.4.3 Study III 
Patients were restricted regarding presence of chronic kidney disease and survival until day 
two. Risk factors were analyzed with multiple logistic regression. There were obvious 
differences in injury severity and associated variables at baseline between the AKI and non-
AKI group, which implies that the risk factors associated with AKI should be interpreted with 
caution in this retrospective study. However, the point estimates for the associations between 
risk factors and AKI were in general very similar before and after adjustment suggesting that 
the findings are robust. 
6.1.4.4 Study IV 
The trauma patients and the control group were matched by age, gender and municipality. 
Stratified analyses based on injury severity and external causes of death were performed. 
Although all studies used methods and models to adjust for measured confounders, the effect 
of unmeasured confounders could never be ruled out. Moreover, there is little consensus on 
how to build regression models, which variables to include and which to omit. 
6.1.5 Random errors 
The results in medical and epidemiological studies are always affected by biologic variation 
and chance. In general, the study population is a sample from a source population on which 
we want to make inferences. The magnitude of uncertainty regarding true differences 
between groups in the source population is reflected by p-values and CI, which will be 
affected by sample size. The p-value is the probability that the difference between groups 
found in a study is caused by chance, given the null hypothesis of no difference between 
these groups in the source population from which we drew our samples. A low p-value 
indicates that it is very unlikely that a difference as large as the one found is caused by 
random error only. The CI reflects the interval in which 95 % of our point estimates will be 
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placed if we resampled new study populations from the source population. Hence, if the 95 % 
CI for a particular value includes the true value of the source population we do not know. 
The large sample sizes in Study I and Study IV reduces the likelihood of random errors. Since 
the CI for the association between β-blocker use and mortality in study II include 1, we 
cannot exclude an effect undetected due to lack of power, i.e. a type I error. In Study III, the 
CIs for several of the included independent variables are wide due to low numbers increasing 
the uncertainty of these associations. Moreover, the somewhat unexpected finding that there 
was no increased risk of post-injury AKI despite the occurrence of sepsis might be erroneous, 
i.e. a type II error. 
 
6.2 INTERPRETATION OF FINDINGS 
6.2.1 Risk factors for traumatic events 
Socio-economic status is widely considered to be of tremendous importance to general 
health. A universal definition of socio-economic status, or socio-economic position, is 
lacking making comparisons between studies and countries difficult. Education and income at 
an individual level, as used in Study I, are probably the most commonly used proxies but the 
methodological approach to define them varies.128 Although the association between a low 
socio-economic status and the risk of specific injuries has been explored previously, these 
analyses have not included comorbidities and injury severity in the same analysis. Moreover, 
there appears to be a gap of knowledge regarding causality; how does differences in socio-
economic status translate into increased risk of trauma and poor outcome?29 
Our results indicate that this association is not fully explained by differences in the 
prevalence of comorbidities or drug abuse. Several conceptual models have been proposed 
including different exposure to hazards, different capacities to avoid risk and different 
opportunities for minimizing physical, psychological and social consequences of injuries.25 In 
addition to the increased risk of trauma, individuals with a low socio-economic position have 
an increased risk of poor physical and physiological outcome if they survive the initial 
injury.128 
The risk of experiencing trauma while intoxicated is obvious and needs no further studies. 
Thus, legal and political actions to reduce the availability of legal and illegal drugs in general 
and in specific situations such as the traffic is likely to reduce the occurrence of traumatic 
events. Although the success of preventive efforts could be difficult to appreciate in short 
term perspective the implementation of evidence-based measures is effective; the reduction of 
road traffic deaths by 50-75 % in high-income countries and the reduction of child injuries by 
80 % in Sweden in the last decades are two examples.2 The risk of trauma being the greatest 
with a recent diagnosis of drug abuse points to the particular importance of an active drug 
abuse, which should alert the clinician caring for these patients. 
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The association between psychiatric disorders and trauma risk is supported by previous 
results from population-based studies suggesting an increased risk of accidental death with 
several mental comorbidities. The increased risk is not fully explained by comorbid substance 
abuse, and accidental death is more common than suicide among these patients.129 Our 
findings, with psychiatric disorders being a significant risk factor after adjustment for drug 
abuse supports this. The causal link between psychiatric disorders and trauma is thus far from 
elucidated and goes beyond intoxication and suicide attempts. The deprivation of sleep with 
several psychiatric disorders, side effects from drugs or relative over-dosing could be 
contributing to the risk of trauma. Moreover, several psychiatric disorders are associated with 
risk-taking or self-destructive behavior.129 
Somatic comorbidity is not only associated with increased risk of trauma, as noted in Study I, 
but also with increased risk of readmission after discharge, as well as increased short- and 
long-term mortality after traumatic events.23,37,38,130 Notably, recent treatment for a somatic 
disease increased the risk of severe trauma and it could be a marker of more active disease or 
lower physiologic reserve. Of importance is the identification of the elderly patient with a 
somatic disorder that makes him or her unfit to drive. The adequate assessment and 
identification of these individuals is challenging but could reduce the risk of trauma.131  
 
6.2.2 β-blockade in the peri-traumatic period 
β-blockade has emerged as a potential intervention following severe trauma after the 
publication of several reports suggesting that post-traumatic administration is associated with 
reduced mortality and positive outcomes.132-149 The majority of these studies have focused on 
TBI, and β-blocker administration has been recommended to victims of severe TBI after 
hemodynamic stabilization.150 In addition, the absence of a therapeutic agent that reduces the 
incidence or severity of MOF together with positive reports from other areas of critical illness 
has increased the interest in β-blockade within the peri-traumatic period.59,60 
Several plausible mechanisms for a protective effect of β-blockers in the trauma setting have 
been presented. A general cardiovascular protective effect is likely in an era of aging trauma 
patients with a substantial burden of comorbidities.133,139 This is supported by a lower 
incidence of myocardial injury noted after post-traumatic administration of atenolol 
compared to placebo.132 
Excess catecholamine release and subsequent hyper-metabolism may be harmful as well, 
especially in TBI, and β-blockade could be protective by attenuating this effect.151-153 
Moreover, β-blockers have complex immunological and hematologic effects not fully 
understood at the present time, which may be of clinical significance.137,144,152 Finally, a 
proposed link between traumatic injuries, elevated levels of catecholamines and endothelial 
injury resulting in coagulopathy and organ failure have been presented and this chain of 
events could be a potential therapeutic target.56 
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In study II, patients using β-blockers at the time of trauma had a twofold increase in the odds 
of death compared to non-users. Thus, at the time of admission, β-blockade use could be seen 
as a marker of increased risk for poor outcome and as a proxy for frailty that should alert the 
clinician. After adjustment for trauma-related factors and baseline imbalances, comorbidities 
in particular, this association was no longer apparent. This indicates that β-blockade per se 
does not increase the risk of death beyond the effects of age, comorbidity and injury severity.  
We hypothesized that β-blockade would be protective after adjustment for important 
confounders but such an effect could not be seen, neither in the full trauma cohort nor in the 
subgroup with severe TBI. We cannot rule out that there might be such an effect, but it is not 
likely that further studies using the same methodology could answer this question. Not 
surprisingly, the users and non-users of β-blockade differed significantly at baseline 
regarding age and comorbidity. Is it possible to completely adjust for these differences 
regardless of statistical approach? The OR for the association between β-blockade was 
strikingly consistent at approximately one, regardless of how the logistic regression was 
modeled regarding age, comorbidity or injuries. Moreover, the addition of for example 
ischemic heart disease to the model did not change the OR for the association between β-
blocker and death, or the discriminating capacity of the model. This indicates that any 
unmeasured confounder not included in the study must have an enormous impact to alter the 
results significantly. One might argue that markers of organ failure instead of 30-day 
mortality should be used to evaluate a treatment that is supposed to reduce the incidence and 
severity of MOF. The absence of these data in Study II is a weakness and the inclusion of 
such parameters could have provided valuable information. 
If our observations are valid, why is β-blockade prior to hospitalization protective in general 
ICU and septic patients but not in the trauma setting?154-156 A notable difference between 
these studies and Study II is the lower, or similar, unadjusted mortality among β-blocker 
users compared to non-users, despite a higher prevalence of comorbidities. This suggests a 
different case mix compared to our material or unmeasured confounders, for example a 
healthy user effect. In addition, the protective effect may be restricted to those with a 
cardiovascular reason for admission to the ICU.154 
Another aspect is the in-hospital continuation versus discontinuation of chronic β-blocker 
treatment. Studies in patients with acute respiratory failure, heart failure and sepsis have 
consistently shown a decreased risk of death if β-blocker therapy is continued in-hospital.157-
159 Moreover, the peri-operative continuation of β-blockers in non-cardiac surgery for patients 
receiving this medication is a Class I recommendation according to European guidelines.160 
We found no association between β-blockade and shock, and no clinically important 
difference in blood pressure on arrival between users and non-users in Study II. With the 
apparent risks associated with discontinuation, our findings may support early reinstitution of 
β-blockers in the trauma setting in the absence of hemodynamic compromise, although at a 
low level of evidence. 
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Regarding post-traumatic administration of β-blockers to patients previously naive to 
treatment, our data provide no answer. As previously mentioned, this has been recommended 
in severe TBI with hemodynamic stability.150 There are some aspects, however, that should 
be addressed. Firstly, no large prospective RCT with clear allocation has yet been presented. 
Secondly, individuals exposed to β-blockers in the majority of retrospective studies published 
had more severe injuries, more complications and a longer length of stay compared to 
unexposed, but reduced mortality in unadjusted analysis. In addition, the finding that the 
protective effect of β-blockers is lost in several reports when early deaths are excluded 
suggests a survival bias.134,136,140 In conclusion, β-blockers are a rational option in the 
hypertensive patient after trauma but RCTs are needed before we can recommend it to other 
groups of patients outside clinical studies. 
6.2.3 Acute kidney injury 
AKI in patients treated in the ICU is a strong marker of disease severity and consistently 
associated with increased risk of death. Although hemorrhagic shock and hypoperfusion may 
cause direct ischemic lesions to the kidney, the pathophysiology of post-traumatic AKI is 
complex and not fully understood.161 Obviously, there are patient-related risk factors that we 
are unable to address; in Study III male gender, age, diabetes and other important 
comorbidities were all significantly associated with subsequent AKI. These entities, which 
are in line with previous reports, characterize a high-risk patient in need of special 
attention.70,71,162 
Unfortunately, few interventions targeted at preventing AKI in high-risk ICU-patients have 
been proven successful in clinical trials.163 In sepsis, a higher compared to a lower blood 
pressure target reduced the need for renal replacement therapy in patients with chronic 
hypertension.164 This effect, however, was not associated with reduced mortality and the 
strategy was associated with an increased incidence of atrial fibrillation. A higher blood 
pressure target, when bleeding control is achieved, might be of advantage for the trauma 
patient with chronic hypertension as well. 
The strong association between all included markers of injury severity and shock highlights 
the need for bleeding control, restoration of circulating volume and homeostasis. Although 
massive transfusion was associated with an increased risk of AKI in Study III this should 
probably be interpreted as a marker of injury severity beyond that measured in scoring 
systems. Current evidence and recommendations strongly imply that the bleeding, 
traumatized patient should be treated with blood and blood products to avoid death by 
exsanguination.14,15 Bleeding control and the reversal of shock is likely of benefit regarding 
AKI risk as well. 
Avoiding interventions or treatments that increases the risk of AKI is of as equal importance 
as preventive measures. Hetastarches are strongly associated with AKI in sepsis and the US 
Food and Drug Administration have advised not to use HES in critically ill patients.18,84,85,165 
This association has been less clear in elective surgery and HES is still widely used.166 In 
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trauma, older HES-solutions (450/0.7) have been associated with increased AKI risk, in 
particular in blunt trauma.86,87 Higher, compared to lower, volumes of HES 130/0.4 were not 
associated with increased risk of AKI in a retrospective study on elderly trauma patients.167 In 
addition, a single center prospective RCT showed decreased incidence of AKI in penetrating 
trauma with the administration of HES 130/0.4 compared to saline.88 Although clinical 
recommendations in general should be based on prospective studies, the results from Study 
III indicate that resuscitation with HES should be avoided in trauma patients. Moreover, a 
dose-response association was noted with a significantly increased risk of AKI already after 
the administration of 500 ml HES suggesting that even low doses may be harmful 
(unpublished data). 
Contrast associated AKI (CA-AKI) is a diagnosis of exclusion and the risk may be 
overestimated.163,168 Nevertheless, administration of iodinated radio contrast media has been 
associated with post-traumatic AKI although results are diverging.72,81,169,170 Since almost 
100 % of included patients in study III received contrast media for computed tomography the 
addition of CA-AKI to the AKI incidence is difficult to evaluate. However, the finding that 
larger doses of contrast media (defined as more than one standard dose within the first day) 
did not increase the risk of AKI is reassuring; radiologic examinations and interventions that 
reduce the possibility of missed injuries and contribute to bleeding control is probably 
beneficial for the patient as well as for the kidneys. 
One quarter of AKI patients were treated with CRRT, none of the survivors however were 
dialysis dependent by three months or one year. This is in line with previous findings in the 
trauma setting suggesting a good potential for renal recovery if the patients is discharged 
alive from the ICU.171 
6.2.4 Excess late mortality 
Clinical experience and a magnitude of literature suggest that the full impact of trauma 
cannot be measured solely by short-term measurements, e.g. in-hospital or 30-day mortality. 
Factors such as quality of life, the ability to return to work and long-term mortality have 
emerged as important topics in trauma research. Previous studies suggest that age, significant 
comorbidity, injury severity, discharge destination and socio-economic factors all contribute 
to the risk of late, post-discharge death after trauma.23,93,94,172 The results from study IV add to 
this knowledge by showing that there is a significant increase in mortality several years after 
trauma in a publicly financed health care system such as the Swedish as well. Moreover, the 
causes of excess late mortality compared to the background population were identified thus 
providing an opportunity to improve follow-up and care for these patients. 
Simplified, two subgroups of deceased patients could be identified; older individuals with a 
high prevalence of somatic comorbidity dying from cardiovascular disorders and neoplasms, 
and younger patients with psychiatric disorders and drug abuse dying from a new traumatic 
event, suicide or intoxication. The finding that the presence of important somatic 
comorbidities, especially among the elderly, has a profound effect on long-term survival is 
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not surprising. Trauma could for these individuals be seen as a marker of frailty and disease 
progression and some of these deaths might be unavoidable and due to age and underlying 
diseases. It has been shown that each additional chronic comorbidity increases the risk of 
hospital readmission significantly after traumatic injuries among elderly.130 Risk assessment 
and targeted interventions prior to discharge might be beneficial among high-risk elderly 
patients in general.173 It is plausible to assume that this may be of value for trauma patients as 
well, but this has not been elucidated at present time. 
RCTs comparing admittance to inpatient rehabilitation facilities versus other forms of post 
acute-phase care after multiple trauma are lacking.174 Stating that, well-performed 
epidemiological studies have suggested that post-traumatic inpatient rehabilitation improves 
functional status to a significant degree and reduces long-term mortality.175 In addition, in a 
large study from the US, patients of all age groups discharged to a skilled nursing facility 
were more likely to die than those discharged home, whereas patients discharged to 
rehabilitation were not.93 Inpatient rehabilitation is expensive and resource demanding but it 
is probably beneficial for the severely injured. In a health care system with limited resources 
the challenge is to identify patients that will benefit the most from these interventions. 
The high proportion of recurrent trauma and external causes of death in study IV is notable. 
The concept of trauma recidivism is old but still valid and seems to be consistent in different 
parts of the world.176,177 The presence of psychiatric comorbidities and drug abuse is 
associated with de novo-trauma, as noted in Study I, but also overrepresented among those 
that died from external causes in Study IV. Individuals with these characteristics are a 
challenge to the health care system and to society alike, and simple solutions and 
interventions are unlikely to be found. 
Although hospitalization caused by injuries has decreased in the 21st century, with fewer 
admissions after traffic accidents in particular, death caused by assault has increased to 
historically high levels among young males in Sweden in the last years.6 Moreover, death due 
to intoxication with prescribed or illegal drugs have increased which is of particular concern. 
Data from the US suggest that there is an alarming “opioid epidemic”, with opioid analgesics 
now being responsible for more deaths than suicide and motor vehicle crashes combined.178 
When converted, the total prescription of therapeutic opioids in the US in 2010 where enough 
to provide every adult citizen with 5 mg of hydrocodone every 6 hours for 45 days. Although 
prescriptions in Sweden have increased, studies indicate that the “epidemic” noted elsewhere 
cannot be seen at the present time.179 Nevertheless, the prescription pattern of opioids among 
traumatized patients is largely unknown and the potential for health care associated opioid 
use and misuse in this group of patients warrants caution. In the absence of positive evidence 
for opioid use in non-malignant pain, long-term treatment after trauma should be avoided. 
Further studies are needed to elucidate this topic. 
The presented results, with the majority of post-traumatic deaths occurring beyond 30 days, 
highlight the importance of long-term follow-up to fully address trauma mortality. This is 
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important for further improvement in trauma care, for the ability to compare results and when 
evaluating interventions and treatment strategies. 
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7 CONCLUSIONS 
Low education, low income, psychiatric- and somatic comorbidities as well as substance 
abuse are all independently associated with the risk of becoming a trauma victim. Active 
substance abuse in particular influences trauma risk. This knowledge might be used for injury 
prevention among risk individuals. 
Pre-traumatic treatment with β-blockers appears to have no association per se to short-term 
mortality after adjustment for relevant confounders. The patient using β-blockers should 
however be seen as a high-risk individual with an increased risk of death due to a high 
prevalence of significant comorbidity. 
AKI is common among intensive care treated patients after severe injury and strongly related 
to increased short- and long-term mortality. The risk of end-stage renal disease and dialysis 
dependency seems to be low among survivors. Somatic comorbidities including diabetes 
together with markers of injury severity are among the non-modifiable risk factors for AKI. 
The administration of HES seems to be associated with AKI and cannot be justified in the 
trauma setting at present time. 
Individuals admitted with multiple trauma have an increased risk of death for at least three 
years after injury compared to uninjured controls of the same age and gender. The excess 
mortality is largely attributed to trauma recidivism, intoxications and suicide. If these insights 
could be translated into targeted secondary prevention it could improve outcome. 
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